BTAI:NSD-BioXcel Therapeutics, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 34.93

Change

+0.89 (+2.61)%

Market Cap

USD 0.81B

Volume

0.29M

Average Target Price

USD 82.25 (+135.47%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

BioXcel Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of adrenergic receptor agonist dexmedetomidine for the treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immune activator for the treatment of prostate and pancreatic cancers, and solid tumors. BioXcel Therapeutics, Inc. has a collaboration with collaboration with the VA Connecticut Healthcare System and the Yale University Medical School for patients suffering from post-traumatic stress disorder related to alcohol and substance abuse disorder. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut.

Company Website : http://www.bioxceltherapeutics.com

Address : 555 Long Wharf Drive, New Haven, CT, United States, 06511

Employees : 50

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : 1.21

52 Week High : 67.74

Short Ratio : 6.53

52 Week Low : 29.20

Shorted Shares : 3,353,565

200 Day Moving Average : 48.17

Shorted Shares Previous Month : 3,707,133

50 Day Moving Average : 41.23

Shares Held By Insiders : 387.01%

Short Percentage : 14.00%

Shares Held by Institutions : 55.45%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-04-21 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

+12.72 (+8.11%)

 USD61.85B N/A N/A
VRTX Vertex Pharmaceuticals Incorpo..

-0.40 (-0.18%)

 USD56.98B 21.40 15.53
REGN Regeneron Pharmaceuticals, Inc

+2.06 (+0.41%)

 USD54.04B 16.53 12.83
ALXN Alexion Pharmaceuticals, Inc

+1.90 (+1.14%)

 USD36.79B 61.23 35.79
BNTX BioNTech SE

+5.62 (+3.60%)

 USD36.10B -99,999.99 N/A
BGNE BeiGene, Ltd

+9.25 (+3.16%)

 USD27.46B N/A N/A
SGEN Seagen Inc

+2.73 (+1.89%)

 USD26.25B 42.96 35.78
RPRX Royalty Pharma plc

+1.34 (+3.23%)

 USD25.16B 22.60 15.19
GMAB Genmab A/S

+0.82 (+2.29%)

 USD23.17B 26.59 3.31
CVAC CureVac N.V

+2.16 (+1.95%)

 USD21.12B N/A N/A

ETFs Containing BTAI

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -24.39% 18% F 10% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -24.39% 18% F 10% F
Trailing 12 Months  
Capital Gain 20.82% 46% F 27% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 20.82% 46% F 25% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 144.74% 93% A 96% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 144.74% 93% A 96% A
Risk Return Profile  
Volatility (Standard Deviation) 227.64% 10% F 6% F
Risk Adjusted Return 63.58% 88% B+ 81% B-
Market Capitalization 0.81B 67% D+ 60% D-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 4.16 54% F 40% F
Price / Cash Flow Ratio -12.28 66% D 79% C+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -70.35% 44% F 17% F
Return on Invested Capital -70.46% 32% F 11% F
Return on Assets -39.57% 25% F 8% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 6.53 27% F 12% F
Short Percent 22.55% 4% F 7% F
Beta 1.21 63% D 46% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector